Optimi Health Corp., a pharmaceutical company specializing in psychedelic drug products, has achieved a significant milestone by listing its common shares on the Nasdaq Capital Market. The Vancouver-based company will trade under the new ticker symbol "OPTH," marking a major step in its corporate growth strategy. This uplisting is accompanied by an underwritten public offering aimed at raising approximately US$15 million to fuel its expansion plans.
Details of the Public Offering
The company has priced its offering of 2,400,000 common shares at a public price of US$6.25 per share. This initiative is expected to generate gross proceeds of around US$15 million, before deducting underwriting discounts and other expenses. The underwriter also holds an option to purchase up to an additional 360,000 common shares, potentially increasing the total capital raised.
Joseph Gunnar & Co., LLC is serving as the sole book-running manager for this significant financial transaction. The offering, which was filed with the U.S. Securities and Exchange Commission, is anticipated to close on or about May 21, 2026. This process is subject to the satisfaction of customary closing conditions as outlined in the prospectus.
Strategic Use of Capital
Optimi Health intends to allocate the net proceeds from the offering toward several key growth initiatives. A primary focus will be on scaling the production and distribution of its existing psychedelic drug products within its current markets. This investment aims to enhance manufacturing capacity and streamline supply chain operations to meet growing demand for regulated therapies.
Beyond bolstering current operations, the capital will be instrumental in funding the company's expansion into new territories, with a specific emphasis on the United States. The funds will also support sales growth initiatives, general working capital, and other operating expenses. Management will retain broad discretion over the final allocation of the net proceeds to best serve the company's strategic objectives.
Corporate Restructuring and Market Presence
In preparation for its Nasdaq debut, Optimi Health executed a consolidation of its outstanding common shares. This move, effective May 19, 2026, was structured on a basis of one post-consolidation share for every thirty pre-consolidation shares. The restructuring was a strategic prerequisite for the uplisting and aimed to align the company's capital structure with exchange requirements.
As a commercial-stage pharmaceutical firm, Optimi operates as a Health Canada-licensed manufacturer of GMP-grade psychedelic compounds. Its core products include validated MDMA and botanical psilocybin, produced at its facilities in British Columbia. The company is positioned to supply both active pharmaceutical ingredients and finished dosage forms for mental health therapies.
Optimi currently serves regulated clinical and therapeutic programs on an international scale. Its products are prescribed to patients in Australia under the country's Authorized Prescriber Scheme. In Canada, access to its therapies is available through the federal Special Access Program, demonstrating its established presence in the global market.
The successful uplisting to the Nasdaq and the accompanying US$15 million public offering represent a transformative moment for Optimi Health Corp. This strategic maneuver not only enhances the company's visibility and access to a broader investor base but also provides the necessary capital for significant expansion. As the market for regulated psychedelic therapies continues to evolve, Optimi is now better positioned to solidify its leadership and advance its mission.